 Pyridones
"Pyridones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridine derivatives with one or more keto groups on the ring.
| Descriptor ID |
D011728
|
| MeSH Number(s) |
D03.383.725.791
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridones".
Below are MeSH descriptors whose meaning is more specific than "Pyridones".
This graph shows the total number of publications written about "Pyridones" by people in this website by year, and whether "Pyridones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1996 | 1 | 1 | 2 | | 2003 | 0 | 1 | 1 | | 2006 | 2 | 0 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 3 | 0 | 3 | | 2013 | 3 | 4 | 7 | | 2014 | 2 | 1 | 3 | | 2015 | 6 | 2 | 8 | | 2016 | 5 | 5 | 10 | | 2017 | 4 | 2 | 6 | | 2018 | 2 | 5 | 7 | | 2019 | 2 | 2 | 4 | | 2020 | 4 | 5 | 9 | | 2021 | 5 | 5 | 10 | | 2022 | 0 | 6 | 6 | | 2023 | 2 | 5 | 7 | | 2024 | 7 | 3 | 10 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyridones" by people in Profiles.
-
Liu J, Edwards Mayhew RG, Imbornoni LM, Jung JL, Oliver SCN, Foreman NK, Mulcahy Levy JM, Hemenway M, McCourt EA. Pediatric MEK inhibitor-associated retinopathy: 8-year experience at a tertiary academic center and report of 2 cases. J AAPOS. 2025 Apr; 29(2):104178.
-
Powis KM, Pinilla M, McMorrow F, Stek A, Brooks KM, Shapiro DE, Knowles K, Eke AC, Greene E, Agwu A, Topete L, Browning R, Chakhtoura N, Arora P, Huang X, Best BM, Mirochnick M, Momper JD. Pharmacokinetics and Safety of Bictegravir in Pregnant and Postpartum Persons With HIV and Their Infants. J Acquir Immune Defic Syndr. 2025 Mar 01; 98(3):300-307.
-
Hanke P, Domingo ME, Salanio G, Ahmed K, Hu J, Hendricks K, Howard J, Hashimura T, Guiliano C, Haan BJ, Ng TH, Kelley D, Knight T, Koopman K, Obstoj M, Breeden T, Sirbu D, Romano M, Harpenau A, Konneker R, Acevedo J, Pan N, Edwin SB. Apixaban versus warfarin for treatment of venous thromboembolism in patients with severe renal impairment: a multicenter study. J Thromb Thrombolysis. 2025 Mar; 58(3):380-390.
-
Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, Patel RP, Tan M, Padmanabhan AA, Lemoine J, Fardella E, Zhang Y, Pajarillo R, Chen L, Ugwuanyi O, Markowitz K, Delman D, Angelos MG, Shestova O, Isshiki Y, Blanchard T, B?guelin W, Melnick AM, Linette GP, Beatty GL, Carreno BM, Cohen IJ, Paruzzo L, Schuster SJ, Ruella M. EZH1/EZH2 inhibition enhances adoptive T?cell immunotherapy against multiple cancer models. Cancer Cell. 2025 Mar 10; 43(3):537-551.e7.
-
Rael CT, Das D, Porter J, Lopez-R?os J, Abascal E, Dolezal C, Vaughn MP, Giffenig P, Lopez JM, Stonbraker S, Sun C, Velasco RA, Bitterfeld L, Bockting WO, Bauermeister J. Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study. J Assoc Nurses AIDS Care. 2024 Sep-Oct 01; 35(5):437-449.
-
Haser GC, Balter L, Gurley S, Thomas M, Murphy T, Sumitani J, Leue EP, Hollman A, Karneh M, Wray L, Washington M, Corbin-Johnson D, Condra A, Niles-Carnes L, Smith BL, Armstrong WS, Kalokhe AS, Colasanti JA, Collins LF. Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South. AIDS Res Hum Retroviruses. 2024 Dec; 40(12):690-700.
-
Kousari AE, Wilson MP, Hawkins KL, Bandali MM, Henao-Mart?nez AF, Gardner EM, Erlandson KM. Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV. HIV Res Clin Pract. 2024 12; 25(1):2339576.
-
Ueberroth BE, Lieu CH, Lentz RW. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. J Gastrointest Cancer. 2024 Sep; 55(3):1448-1452.
-
Floyd J, Porragas-Paseiro H, Nguyen C, Moroney MR, Mastroyannis S, Guntupalli SR. Validation of the Safety and Efficacy of Apixaban as Postoperative Thromboembolism Prophylaxis for Patients with Gynecologic Malignancies. Ann Surg Oncol. 2024 Aug; 31(8):5102-5110.
-
Nayir ME, Nwaezeapu KI, Ogedegbe JO, Patel YB, Khan MA, Valle J. Perils of reduced dose apixaban in atrial fibrillation/flutter - A case report with a brief literature review. Am J Med Sci. 2024 08; 368(2):159-161.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|